{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:12:42Z","timestamp":1774577562702,"version":"3.50.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:00:00Z","timestamp":1470096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:00:00Z","timestamp":1470096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"University Medical Centre Ljubljana","award":["20140208"],"award-info":[{"award-number":["20140208"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40272-016-0186-0","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T09:36:33Z","timestamp":1470130593000},"page":"397-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Management of Juvenile Idiopathic Arthritis: A Clinical Guide"],"prefix":"10.1007","volume":"18","author":[{"given":"\u0160tefan","family":"Blazina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u0161per","family":"Markelj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojca Zajc","family":"Avramovi\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nata\u0161a","family":"Toplak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-9092","authenticated-orcid":false,"given":"Tadej","family":"Av\u010din","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"186_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol."},{"key":"186_CR2","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496\u2013504.","journal-title":"Arthritis Rheum."},{"key":"186_CR3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810\u201320.","journal-title":"N Engl J Med."},{"key":"186_CR4","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/art.24777","volume":"60","author":"EH Giannini","year":"2009","unstructured":"Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:2794\u2013804.","journal-title":"Arthritis Rheum."},{"key":"186_CR5","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396\u2013406.","journal-title":"N Engl J Med."},{"key":"186_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.12703\/P6-21","volume":"6","author":"T Beukelman","year":"2014","unstructured":"Beukelman T. Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Rep. 2014;6:21.","journal-title":"F1000Prime Rep."},{"key":"186_CR7","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66:1034\u201343.","journal-title":"Arthritis Rheumatol."},{"key":"186_CR8","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase\u00a03, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110\u20137.","journal-title":"Ann Rheum Dis."},{"key":"186_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465\u201382.","journal-title":"Arthritis Care Res."},{"key":"186_CR10","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65:2499\u2013512.","journal-title":"Arthritis Rheum."},{"key":"186_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/art.20860","volume":"52","author":"N Ruperto","year":"2005","unstructured":"Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005;52:563\u201372.","journal-title":"Arthritis Rheum."},{"key":"186_CR12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/rheumatology\/40.11.1309","volume":"40","author":"RG Hull","year":"2001","unstructured":"Hull RG. Guidelines for management of childhood arthritis. Rheumatology. 2001;40:1309\u201312.","journal-title":"Rheumatology."},{"key":"186_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1542\/peds.109.1.109","volume":"109","author":"NT Ilowite","year":"2002","unstructured":"Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics. 2002;109:109\u201315.","journal-title":"Pediatrics."},{"key":"186_CR14","volume-title":"Clinical guideline for the diagnosis and management of juvenile idiopathic arthritis","author":"J Munro","year":"2009","unstructured":"Munro J, National Health and Medical Research Council, et al. Clinical guideline for the diagnosis and management of juvenile idiopathic arthritis. Melbourne: Royal Australian College of General Practitioners; 2009."},{"key":"186_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clim.2011.10.003","volume":"142","author":"G Dueckers","year":"2012","unstructured":"Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol. 2012;142:176\u201393.","journal-title":"Clin Immunol."},{"key":"186_CR16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/acr.22259","volume":"66","author":"S Ringold","year":"2014","unstructured":"Ringold S, Weiss PF, Colbert RA, DeWitt EM, Lee T, Onel K, et al. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res. 2014;66:1063\u201372.","journal-title":"Arthritis Care Res."},{"key":"186_CR17","first-page":"1153","volume":"26","author":"M Cattalini","year":"2008","unstructured":"Cattalini M, Maduskuie V, Fawcett PT, Brescia AM, Ros\u00e9 CD. Predicting duration of beneficial effect of joint injection among children with chronic arthritis by measuring biomarker concentration in synovial fluid at the time of injection. Clin Exp Rheumatol. 2008;26:1153\u201360.","journal-title":"Clin Exp Rheumatol"},{"key":"186_CR18","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/rheumatology\/keh313","volume":"43","author":"F Zulian","year":"2004","unstructured":"Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology. 2004;43:1288\u201391.","journal-title":"Rheumatology."},{"key":"186_CR19","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/1529-0131(199807)41:7<1210::AID-ART10>3.0.CO;2-5","volume":"41","author":"S Padeh","year":"1998","unstructured":"Padeh S, Passwell JH. Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum. 1998;41:1210\u20134.","journal-title":"Arthritis Rheum."},{"key":"186_CR20","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/art.10313","volume":"46","author":"J Neidel","year":"2002","unstructured":"Neidel J, Boehnke M, K\u00fcster RM. The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis. Arthritis Rheum. 2002;46:1620\u20138.","journal-title":"Arthritis Rheum."},{"key":"186_CR21","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1002\/art.21384","volume":"52","author":"B Arabshahi","year":"2005","unstructured":"Arabshahi B, Dewitt EM, Cahill AM, Kaye RD, Baskin KM, Towbin RB, et al. Utility of corticosteroid injection for temporomandibular arthritis in children with juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:3563\u20139.","journal-title":"Arthritis Rheum."},{"key":"186_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/art.21599","volume":"53","author":"GT Brown","year":"2005","unstructured":"Brown GT, Wright FV, Lang BA, Birdi N, Oen K, Stephens D, et al. Clinical responsiveness of self-report functional assessment measures for children with juvenile idiopathic arthritis undergoing intraarticular corticosteroid injections. Arthritis Care Res. 2005;53:897\u2013904.","journal-title":"Arthritis Care Res."},{"key":"186_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12969-015-0021-0","volume":"13","author":"A Oren-Ziv","year":"2015","unstructured":"Oren-Ziv A, Hoppenstein D, Shles A, Uziel Y. Sedation methods for intra-articular corticosteroid injections in juvenile idiopathic arthritis: a review. Pediatr. Rheumatol. 2015;13:28.","journal-title":"Pediatr. Rheumatol."},{"key":"186_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1546-0096-6-1","volume":"6","author":"Y Uziel","year":"2008","unstructured":"Uziel Y, Chapnick G, Rothschild M, Tauber T, Press J, Harel L, et al. Nitrous oxide sedation for intra-articular injection in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2008;6:1.","journal-title":"Pediatr Rheumatol Online J."},{"key":"186_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/BOR.0b013e328329c79d","volume":"21","author":"J Braun","year":"2009","unstructured":"Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol. 2009;21:216\u201323.","journal-title":"Curr Opin Rheumatol."},{"key":"186_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s11926-006-0041-3","volume":"8","author":"PJ Hashkes","year":"2006","unstructured":"Hashkes PJ, Laxer RM. Update on the medical treatment of juvenile idiopathic arthritis. Curr Rheumatol Rep. 2006;8:450\u20138.","journal-title":"Curr Rheumatol Rep."},{"key":"186_CR27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/art.20288","volume":"50","author":"N Ruperto","year":"2004","unstructured":"Ruperto N, Murray KJ, Gerloni V, Wulffraat N, De Oliveira SKF, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50:2191\u2013201.","journal-title":"Arthritis Rheum."},{"key":"186_CR28","first-page":"1845","volume":"20","author":"JW Jundt","year":"1993","unstructured":"Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20:1845\u20139.","journal-title":"J Rheumatol."},{"key":"186_CR29","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMoa041810","volume":"352","author":"E Silverman","year":"2005","unstructured":"Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655\u201366.","journal-title":"N Engl J Med."},{"key":"186_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/ard.2007.075895","volume":"67","author":"A C\u00e9spedes-Cruz","year":"2008","unstructured":"C\u00e9spedes-Cruz A, Guti\u00e9rrez-Su\u00e1rez R, Pistorio A, Ravelli A, Loy A, Murray KJ, et al. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis. 2008;67:309\u201314.","journal-title":"Ann Rheum Dis."},{"key":"186_CR31","first-page":"S122","volume":"28","author":"R Guti\u00e9rrez-Su\u00e1rez","year":"2010","unstructured":"Guti\u00e9rrez-Su\u00e1rez R, Burgos-Vargas R. The use of methotrexate in children with rheumatic diseases. Clin Exp Rheumatol. 2010;28:S122\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"186_CR32","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1136\/annrheumdis-2011-200942","volume":"71","author":"M Bulatovic","year":"2012","unstructured":"Bulatovic M, Heijstek MW, Van Dijkhuizen EHP, Wulffraat NM, Pluijm SMF, de Jonge R. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:1484\u20139.","journal-title":"Ann Rheum Dis."},{"key":"186_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767\u201378.","journal-title":"Lancet."},{"key":"186_CR34","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1016\/j.vaccine.2015.06.086","volume":"33","author":"N Toplak","year":"2015","unstructured":"Toplak N, Av\u010din T. Long-term safety and efficacy of varicella vaccination in children with juvenile idiopathic arthritis treated with biologic therapy. Vaccine. 2015;33:4056\u20139.","journal-title":"Vaccine."},{"key":"186_CR35","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/acr.20183","volume":"62","author":"GS Pileggi","year":"2010","unstructured":"Pileggi GS, de Souza CBS, Ferriani VPL. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res. 2010;62:1034\u20139.","journal-title":"Arthritis Care Res."},{"key":"186_CR36","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1001\/jama.2013.6768","volume":"309","author":"MW Heijstek","year":"2013","unstructured":"Heijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S, de Vries LD, et al. Effects of the live attenuated measles\u2013mumps\u2013rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA. 2013;309:2449\u201356.","journal-title":"JAMA."},{"key":"186_CR37","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/art.20861","volume":"52","author":"E Silverman","year":"2005","unstructured":"Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2005;52:554\u201362.","journal-title":"Arthritis Rheum."},{"key":"186_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/nyas.12436","volume":"1318","author":"C Malattia","year":"2014","unstructured":"Malattia C, Martini A. Glucocorticoids in juvenile idiopathic arthritis. Ann NY Acad Sci. 2014;1318:65\u201370.","journal-title":"Ann NY Acad Sci."},{"key":"186_CR39","first-page":"5","volume":"36","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;36:5\u20138.","journal-title":"N Engl J Med."},{"key":"186_CR40","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763\u20139.","journal-title":"N Engl J Med."},{"key":"186_CR41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/ard.2007.087593","volume":"68","author":"G Horneff","year":"2009","unstructured":"Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68:519\u201325.","journal-title":"Ann Rheum Dis."},{"key":"186_CR42","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/rheumatology\/keq292","volume":"50","author":"V Papsdorf","year":"2011","unstructured":"Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology. 2011;50:214\u201321.","journal-title":"Rheumatology."},{"key":"186_CR43","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/ard.2007.087411","volume":"68","author":"FHM Prince","year":"2009","unstructured":"Prince FHM, Twilt M, ten Cate R, van Rossum MAJ, Armbrust W, Hoppenreijs EPAH, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635\u201341.","journal-title":"Ann Rheum Dis."},{"key":"186_CR44","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.38741","volume":"66","author":"H Schmeling","year":"2014","unstructured":"Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol. 2014;66:2580\u20139.","journal-title":"Arthritis Rheumatol."},{"key":"186_CR45","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096\u2013106.","journal-title":"Arthritis Rheum."},{"key":"186_CR46","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/ard.2009.100354","volume":"69","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69:718\u201322.","journal-title":"Ann Rheum Dis."},{"key":"186_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1203\/PDR.0b013e318208451d","volume":"69","author":"M Kosma\u010d","year":"2011","unstructured":"Kosma\u010d M, Av\u010din T, Toplak N, Simonini G, Cimaz R. Curin \u0160erbec V. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr Res. 2011;69:243\u20138.","journal-title":"Pediatr Res."},{"key":"186_CR48","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/rheumatology\/ket170","volume":"52","author":"J Anink","year":"2013","unstructured":"Anink J, Otten MH, Gorter SL, Prince FHM, van Rossum MAJ, van den Berg JM, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology. 2013;52:1674\u20139.","journal-title":"Rheumatology."},{"key":"186_CR49","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/acr.22214","volume":"66","author":"G Simonini","year":"2014","unstructured":"Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti\u2013tumor necrosis factor\u00a0\u03b1 treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res. 2014;66:1073\u201384.","journal-title":"Arthritis Care Res."},{"key":"186_CR50","doi-asserted-by":"publisher","unstructured":"Kearsley-Fleet L, Davies R, Baildam E, Beresford MW, Foster HE, Southwood TR, et al. Factors associated with choice of biologic among children with juvenile idiopathic arthritis: results from two UK paediatric biologic registers. Rheumatology. doi:10.1093\/rheumatology\/kev429 \n                           (Epub 2016 Jan 4).","DOI":"10.1093\/rheumatology\/kev429"},{"key":"186_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","volume":"28","author":"N Ilowite","year":"2009","unstructured":"Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28:129\u201337.","journal-title":"Clin Rheumatol."},{"key":"186_CR52","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3899\/jrheum.130133","volume":"40","author":"A Tambralli","year":"2013","unstructured":"Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40:1749\u201355.","journal-title":"J Rheumatol."},{"key":"186_CR53","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CLM, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JWR, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460\u20138.","journal-title":"JAMA."},{"key":"186_CR54","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/BOR.0000000000000185","volume":"27","author":"S Gmuca","year":"2015","unstructured":"Gmuca S, Weiss PF. Juvenile spondyloarthritis. Curr Opin Rheumatol. 2015;27:364\u201372.","journal-title":"Curr Opin Rheumatol."},{"key":"186_CR55","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1546-0096-10-14","volume":"10","author":"R Burgos-Vargas","year":"2012","unstructured":"Burgos-Vargas R. The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: a critical appraisal for the pediatric rheumatologist. Pediatr Rheumatol Online J. 2012;10:14.","journal-title":"Pediatr Rheumatol Online J."},{"key":"186_CR56","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s10067-015-3029-4","volume":"34","author":"A Aggarwal","year":"2015","unstructured":"Aggarwal A, Misra DP. Enthesitis-related arthritis. Clin Rheumatol. 2015;34:1839\u201346.","journal-title":"Clin Rheumatol."},{"key":"186_CR57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/BF01450892","volume":"17","author":"JL Huang","year":"1998","unstructured":"Huang JL, Chen LC. Sulphasalazine in the treatment of children with chronic arthritis. Clin. Rheumatol. 1998;17:359\u201363.","journal-title":"Clin. Rheumatol."},{"key":"186_CR58","doi-asserted-by":"publisher","unstructured":"Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database of Syst Rev. 2014;(11):CD004800. doi:10.1002\/14651858.CD004800.pub3.","DOI":"10.1002\/14651858.CD004800.pub3"},{"key":"186_CR59","first-page":"2055","volume":"31","author":"M Henrickson","year":"2004","unstructured":"Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol. 2004;31:2055\u201361.","journal-title":"J Rheumatol."},{"key":"186_CR60","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/art.21121","volume":"52","author":"SML Tse","year":"2005","unstructured":"Tse SML, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum. 2005;52:2103\u20138.","journal-title":"Arthritis Rheum."},{"key":"186_CR61","first-page":"424","volume":"32","author":"B Hugle","year":"2014","unstructured":"Hugle B, Burgos-Vargas R, Inman RD, O\u2019Shea F, Laxer RM, Stimec J, et al. Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol. 2014;32:424\u201331.","journal-title":"Clin Exp Rheumatol."},{"key":"186_CR62","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.3899\/jrheum.110145","volume":"38","author":"MH Otten","year":"2011","unstructured":"Otten MH, Prince FHM, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EPAH, et al. Tumor necrosis factor\u2013blocking agents for children with enthesitis-related arthritis\u2014data from the Dutch Arthritis and Biologicals in Children Register, 1999\u20132010. J Rheumatol. 2011;38:2258\u201363.","journal-title":"J Rheumatol."},{"key":"186_CR63","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","volume":"73","author":"G Horneff","year":"2014","unstructured":"Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part\u00a01 (week\u00a012) of the CLIPPER study. Ann Rheum Dis. 2014;73:1114\u201322.","journal-title":"Ann Rheum Dis."},{"key":"186_CR64","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/acr.22657","volume":"67","author":"R Burgos-Vargas","year":"2015","unstructured":"Burgos-Vargas R, Tse SML, Horneff G, Pangan AL, Kalabic J, Goss S, et al. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res. 2015;67:1503\u201312.","journal-title":"Arthritis Care Res."},{"key":"186_CR65","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/ar4072","volume":"14","author":"G Horneff","year":"2012","unstructured":"Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012;14:230.","journal-title":"Arthritis Res Ther."},{"key":"186_CR66","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Hermann K-GA, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73:817\u201323.","journal-title":"Ann Rheum Dis."},{"key":"186_CR67","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138\u201349.","journal-title":"Lancet."},{"key":"186_CR68","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3899\/jrheum.090952","volume":"36","author":"RAG Russo","year":"2009","unstructured":"Russo RAG, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol. 2009;36:1078\u201382.","journal-title":"J Rheumatol."},{"key":"186_CR69","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasigli\u00e8 D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505\u201315.","journal-title":"Arthritis Rheum."},{"key":"186_CR70","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/RHU.0b013e3181a4f459","volume":"15","author":"A Zeft","year":"2009","unstructured":"Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol. 2009;15:161\u20134.","journal-title":"J Clin Rheumatol."},{"key":"186_CR71","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FHM, Zeft A, Rabinovich CE, van Rossum MAJ, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545\u201355.","journal-title":"Arthritis Rheum."},{"key":"186_CR72","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747\u201354.","journal-title":"Ann Rheum Dis."},{"key":"186_CR73","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40259-015-0123-8","volume":"29","author":"SM Hoy","year":"2015","unstructured":"Hoy SM. Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs. 2015;29:133\u201342.","journal-title":"BioDrugs."},{"key":"186_CR74","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/art.38699","volume":"66","author":"NT Ilowite","year":"2014","unstructured":"Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:2570\u20139.","journal-title":"Arthritis Rheumatol."},{"key":"186_CR75","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2217\/imt.15.104","volume":"8","author":"P Barone","year":"2016","unstructured":"Barone P, Pignataro R, Garozzo MT, Leonardi S. IL-6 blockers in systemic onset juvenile idiopathic arthritis. Immunotherapy. 2016;8:79\u201387.","journal-title":"Immunotherapy."},{"key":"186_CR76","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/art.20944","volume":"52","author":"S Yokota","year":"2005","unstructured":"Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818\u201325.","journal-title":"Arthritis Rheum."},{"key":"186_CR77","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase\u00a0III trial. Lancet. 2008;371:998\u20131006.","journal-title":"Lancet"},{"key":"186_CR78","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/annrheumdis-2012-202310","volume":"72","author":"S Yokota","year":"2013","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, et al. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. Ann Rheum Dis. 2013;72:627\u20138.","journal-title":"Ann Rheum Dis."},{"key":"186_CR79","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385\u201395.","journal-title":"N Engl J Med."},{"key":"186_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2014-000036","volume":"1","author":"A Woerner","year":"2015","unstructured":"Woerner A, Uettwiller F, Melki I, Mouy R, Wouters C, Bader-Meunier B, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open. 2015;1:1\u20139.","journal-title":"RMD Open."},{"key":"186_CR81","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, et al; Childhood Arthritis and Rheumatology Research Alliance. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2012\u201321.","journal-title":"Arthritis Rheum."},{"key":"186_CR82","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/rheumatology\/keq123","volume":"49","author":"AD Billiau","year":"2010","unstructured":"Billiau AD, Loop M, Le PQ, Berthet F, Philippet P, Kasran A, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology. 2010;49:1550\u20138.","journal-title":"Rheumatology."},{"key":"186_CR83","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2217\/pgs.12.214","volume":"14","author":"F Malik","year":"2013","unstructured":"Malik F, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. Pharmacogenomics. 2013;14:305\u201314.","journal-title":"Pharmacogenomics."},{"key":"186_CR84","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.3899\/jrheum.111593","volume":"39","author":"MCFJ de Rotte","year":"2012","unstructured":"de Rotte MCFJ, Bulatovic M, Heijstek MW, Jansen G, Heil SG, van Schaik RHN, et al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol. 2012;39:2032\u201340.","journal-title":"J Rheumatol."},{"key":"186_CR85","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.24087","volume":"61","author":"HM Albers","year":"2009","unstructured":"Albers HM, Wessels JAM, van der Straaten RJHM, Brinkman DMC, Suijlekom-Smit LWA, Kamphuis SSM, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:46\u201351.","journal-title":"Arthritis Rheum."},{"issue":"Suppl 85","key":"186_CR86","first-page":"S126","volume":"32","author":"A Consolaro","year":"2014","unstructured":"Consolaro A, Schiappapietra B, Dalpr\u00e0 S, Calandra S, Martini A, Ravelli A. Optimisation of disease assessments in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2014;32(Suppl 85):S126\u201330.","journal-title":"Clin Exp Rheumatol."},{"key":"186_CR87","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1002\/art.30502","volume":"63","author":"K Baszis","year":"2011","unstructured":"Baszis K, Garbutt J, Toib D, Mao J, King A, White A, et al. Clinical outcomes after withdrawal of anti-tumor necrosis factor\u00a0\u03b1 therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthritis Rheum. 2011;63:3163\u20138.","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 78","key":"186_CR88","first-page":"S98","volume":"31","author":"S Verazza","year":"2013","unstructured":"Verazza S, Negro G, Marafon D, Consolaro A, Martini A, Ravelli A. Possible discontinuation of therapies after clinical remission in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2013;31(Suppl. 78):S98\u2013101.","journal-title":"Clin Exp Rheumatol."},{"key":"186_CR89","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/acr.22477","volume":"67","author":"CY Chang","year":"2015","unstructured":"Chang CY, Meyer RML, Reiff AO. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res. 2015;67:658\u201366.","journal-title":"Arthritis Care Res."},{"key":"186_CR90","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s00296-012-2642-7","volume":"33","author":"Y Cai","year":"2013","unstructured":"Cai Y, Liu X, Zhang W, Xu J, Cao L. Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission. Rheumatol Int. 2013;33:2277\u201382.","journal-title":"Rheumatol Int."},{"key":"186_CR91","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","volume":"371","author":"P Emery","year":"2014","unstructured":"Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014;371:1781\u201392.","journal-title":"N Engl J Med."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-016-0186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-016-0186-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-016-0186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:24:22Z","timestamp":1659111862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-016-0186-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,2]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1007\/s40272-016-0186-0","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,2]]},"assertion":[{"value":"2 August 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Tadej Av\u010din declares speakers bureau (AbbVie, Pfizer, Octapharma) and advisory board (Bristol-Myers Squibb, Octapharma). \u0160tefan Blazina, Ga\u0161per Markelj, Mojca Zajc Avramovi\u010d and Nata\u0161a Toplak have no conflicts of interest that are relevant to the content of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was partially supported by the University Medical Center Ljubljana (research Grant Number 20140208).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}